专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US06713069B1 Compositions and methods for detecting, preventing, and treating African Hemorrhagic Fever 失效
标题翻译：用于检测，预防和治疗非洲出血热的组合物和方法
公开(公告)号：US06713069B1
公开(公告)日：2004-03-30
申请号：US08838128
申请日：1997-04-15
申请人： William R. Gallaher
发明人： William R. Gallaher
IPC分类号： A61K39193
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , C12N2760/14022 , C12N2760/14122
摘要： There is a substantial degree of structural similarity (although not sequence similarity) between the carboxy-terminal one-third of Filovirus glycoprotein and the transmembrane proteins of the very distantly related retroviruses, especially those of avian sarcoma viruses. The high degree of structural similarity implies functional homology as well. A number of compounds that are useful in the diagnosis and treatment of African hemorrhagic fever (“AHF”) are disclosed. AHF infections (e.g., Ebola, Marburg) may be inhibited with low concentrations of peptides or antibodies of low toxicity. For example, analogs of a portion of the natural fusion glycoprotein of a Filovirus may be used to inhibit the normal fusion process of the virus in vivo, thus preventing or limiting infection.
摘要翻译：在病毒糖蛋白的羧基末端三分之一与非常遥远相关的逆转录病毒的跨膜蛋白（特别是禽肉瘤病毒）的跨膜蛋白质之间存在相当程度的结构相似性（尽管不是序列相似性）。高度的结构相似性也意味着功能同源性。公开了一些可用于诊断和治疗非洲出血热（“AHF”）的化合物。可以用低浓度的低毒性肽或抗体来抑制AHF感染（例如埃博拉病毒，马堡）。例如，可以使用病毒的一部分天然融合糖蛋白的类似物来抑制病毒在体内的正常融合过程，从而预防或限制感染。

2. 发明授权

US06585978B1 EIA vaccine and diagnostic 失效
标题翻译： EIA疫苗和诊断
公开(公告)号：US06585978B1
公开(公告)日：2003-07-01
申请号：US09658547
申请日：2000-09-09
申请人： Ronald Montelaro , Bridget Puffer , Feng Li , Charles Issel , Kristina J. Hennessy , Karen K. Brown
发明人： Ronald Montelaro , Bridget Puffer , Feng Li , Charles Issel , Kristina J. Hennessy , Karen K. Brown
IPC分类号： A61K39193
CPC分类号： C07K14/005 , A61K39/12 , A61K39/21 , A61K2039/5254 , A61K2039/545 , A61K2039/552 , A61K2039/55555 , C12N7/00 , C12N2740/15021 , C12N2740/15022 , C12N2740/15034 , C12N2740/15061 , Y10S424/82
摘要： The invention provides an equine infectious anemia (EIA) vaccine that provides immunity to mammals, especially equines, from infection with equine infectious anemia virus (EIAV) and which allows differentiation between vaccinated and non-vaccinated, but exposed, mammals or equines. Preferably said vaccine encompasses at least one mutation in an EIAV which produces a non-functional gene in the vaccine virus that is always expressed in disease-producing wild-type EIA viruses. Additionally, said EIA vaccine virus cannot cause clinical disease in mammals or spread or shed to other mammals including equines.
摘要翻译：本发明提供了一种马传染性贫血（EIA）疫苗，其能够免受哺乳动物，特别是马感染马传染性贫血病毒（EIAV）的免疫，并且其允许接种疫苗接种但未暴露的哺乳动物或马之间的分化。优选地，所述疫苗包括EIAV中的至少一个突变，其在疫苗病毒中产生总是在产生疾病的野生型EIA病毒中表达的非功能性基因。此外，所述EIA疫苗病毒不能在哺乳动物中引起临床疾病，或传播或流传至包括马的其他哺乳动物。

3. 发明授权

US06461616B1 EIAV p26 deletion vaccine and diagnostic 失效
标题翻译： EIAV p26缺失疫苗和诊断
公开(公告)号：US06461616B1
公开(公告)日：2002-10-08
申请号：US09659026
申请日：2000-09-09
申请人： Ronald Montelaro , Jodi Craigo , Charles Issel , Bridget Puffer , Kristina J. Hennessy , Karen K Brown
发明人： Ronald Montelaro , Jodi Craigo , Charles Issel , Bridget Puffer , Kristina J. Hennessy , Karen K Brown
IPC分类号： A61K39193
CPC分类号： C07K14/005 , A61K39/00 , A61K2039/5254 , C12N2740/15022
摘要： Disclosed herein is a vaccine which provides immunity to mammals from infection and/or disease caused by a lentivirus, such as equine infectious anemia virus, human immunodeficiency virus (HIV), feline immunodeficiency virus (FIV), bovine immunodeficiency virus (BIV) or simian immunodeficiency virus (SIV) said composition comprising a deletion in a gene that blocks replication of the virus in vivo. Preferably said composition encompasses at least one deletion in a lentivirus which provides protection from exposure to wild-type lentiviruses. It also encompasses a marker vaccine in which a foreign gene is inserted into the gene-deleted region, said inserted gene providing a diagnostic tool for use in vaccinated mammals. The scope of the invention encompasses an EIAV vaccine that allows equines to be safely vaccinated and protected from disease without converting to a seropositive status on the Coggin's Test or any other test which measures p26.
摘要翻译：本文公开了一种疫苗，其对哺乳动物免受由慢病毒引起的感染和/或疾病，例如马传染性贫血病毒，人免疫缺陷病毒（HIV），猫免疫缺陷病毒（FIV），牛免疫缺陷病毒（BIV）或猿猴免疫缺陷病毒（SIV）所述组合物包含在体内阻断病毒复制的基因中的缺失。优选地，所述组合物包含慢病毒中的至少一种缺失，其提供防止暴露于野生型慢病毒的保护。它还包括其中将外源基因插入基因缺失区域的标记疫苗，所述插入基因提供用于接种哺乳动物的诊断工具。本发明的范围包括EIAV疫苗，其允许马被安全地接种疫苗并免受疾病的侵害，而不会在Coggin's Test或任何其他测量p26的测试中转变为血清阳性状态。

4. 发明授权

US06638514B1 Multivalent dengue virus vaccine 有权
标题翻译：多价登革热病毒疫苗
公开(公告)号：US06638514B1
公开(公告)日：2003-10-28
申请号：US09535117
申请日：2000-03-24
申请人： Kenneth H. Eckels , Joseph R. Putnak , Doria R. Dubois , Bruce L. Innis , Charles H. Hoke , Sun Wellington , Niranjan Kanessa-thasan
发明人： Kenneth H. Eckels , Joseph R. Putnak , Doria R. Dubois , Bruce L. Innis , Charles H. Hoke , Sun Wellington , Niranjan Kanessa-thasan
IPC分类号： A61K39193
CPC分类号： C12N7/00 , A61K39/12 , A61K2039/5254 , A61K2039/70 , C12N2770/24134 , C12N2770/24164 , Y02A50/386
摘要： The present invention provides vaccine compositions of attenuated dengue virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against all four dengue virus serotypes by administration of attenuated dengue-1, dengue-2, dengue-3, and dengue-4 virus.
摘要翻译：本发明提供了减毒登革热病毒的疫苗组合物。更具体地说，减毒病毒是通过PDK细胞中连续传代产生的。本发明还提供了通过施用减毒登革热-1，登革热2，登革热-3和登革热-4病毒刺激个体的免疫系统以诱导针对所有四种登革热病毒血清型的保护的方法。

5. 发明授权

US06537557B1 Attenuated dengue-4 virus vaccine 有权
标题翻译：登革4病毒疫苗减毒
公开(公告)号：US06537557B1
公开(公告)日：2003-03-25
申请号：US09534726
申请日：2000-03-24
申请人： Kenneth H. Eckels , Joseph R. Putnak , Doria R. Dubois , Bruce L. Innis , Charles H. Hoke , David Vaughn
发明人： Kenneth H. Eckels , Joseph R. Putnak , Doria R. Dubois , Bruce L. Innis , Charles H. Hoke , David Vaughn
IPC分类号： A61K39193
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/5254 , A61K2039/545 , A61K2039/57 , A61K2039/70 , C12N7/00 , C12N2770/24122 , C12N2770/24134 , C12N2770/24164 , Y02A50/386
摘要： The present invention provides vaccine compositions of attenuated dengue-4 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-4 virus by administration of attenuated dengue-4 virus.
摘要翻译：本发明提供了减毒登革热-4病毒的疫苗组合物。更具体地说，减毒病毒是通过PDK细胞中连续传代产生的。本发明还提供刺激个体的免疫系统以通过施用减毒登革热-4病毒诱导针对登革热-4病毒的保护的方法。

6. 发明授权

US06592874B2 Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis 失效
公开(公告)号：US06592874B2
公开(公告)日：2003-07-15
申请号：US09507362
申请日：2000-02-18
申请人： Sondra Schlesinger , Ilya Frolov
发明人： Sondra Schlesinger , Ilya Frolov
IPC分类号： A61K39193
CPC分类号： C07K14/005 , A61K39/00 , A61K48/00 , C12N7/00 , C12N15/79 , C12N15/86 , C12N2770/36121 , C12N2770/36122 , C12N2770/36143 , C12N2770/36162 , C12N2830/005 , C12N2830/006 , C12N2830/42 , C12N2830/48 , C12N2840/20 , C12N2840/203 , C12N2840/44
摘要： Isolated nucleic acid molecules are disclosed, comprising an alphavirus nonstructural protein gene which, when operably incorporated into a recombinant alphavirus particle, eukaryotic layered vector initiation system, or RNA vector replicon, has a reduced level of vector-specific RNA synthesis, as compared to wild-type, and the same or greater level of proteins encoded by RNA transcribed from the viral junction region promoter, as compared to a wild-type recombinant alphavirus particle. Also disclosed are RNA vector replicons, alphavirus vector constructs, and eukaryotic layered vector initiation systems which contain the above-identified nucleic acid molecules.

7. 发明授权

US06511667B1 Attenuated dengue-2 virus vaccine 有权
标题翻译：登革2病毒疫苗减毒
公开(公告)号：US06511667B1
公开(公告)日：2003-01-28
申请号：US09534725
申请日：2000-03-24
申请人： Kenneth H. Eckels , Joseph R. Putnak , Doria R. Dubois , Bruce L. Innis , Charles H. Hoke , David Vaughn , Erik A. Henchai , Niranian Kanesa-thasan
发明人： Kenneth H. Eckels , Joseph R. Putnak , Doria R. Dubois , Bruce L. Innis , Charles H. Hoke , David Vaughn , Erik A. Henchai , Niranian Kanesa-thasan
IPC分类号： A61K39193
CPC分类号： C12N7/00 , A61K39/12 , A61K2039/525 , A61K2039/5254 , A61K2039/70 , C12N2770/24134 , C12N2770/24161 , Y02A50/386
摘要： The present invention provides vaccine compositions of attenuated dengue-2 virus. More specifically, the attenuated virus is produced by serial passage in PDK cells. The invention also provides methods for stimulating the immune system of an individual to induce protection against dengue-2 virus by administration of attenuated dengue-2 virus.
摘要翻译：本发明提供了减毒登革热-2病毒的疫苗组合物。更具体地说，减毒病毒是通过PDK细胞中连续传代产生的。本发明还提供刺激个体的免疫系统以通过施用减毒登革热-2诱导针对登革热-2病毒的保护的方法。

8. 发明授权

US06410032B1 Attenuated forms of bovine viral diarrhea virus 失效
标题翻译：牛病毒性腹泻病毒的减毒形式
公开(公告)号：US06410032B1
公开(公告)日：2002-06-25
申请号：US09702330
申请日：2000-10-31
申请人： Xuemei Cao , Michael G. Sheppard
发明人： Xuemei Cao , Michael G. Sheppard
IPC分类号： A61K39193
CPC分类号： C07K14/005 , A61K39/12 , A61K2039/5254 , A61K2039/552 , C12N7/00 , C12N2770/24322 , C12N2770/24334 , C12N2770/24361
摘要： The present invention is directed to a method of producing attenuated forms of bovine viral diarrhea (BVD) virus by mutating the Npro protease gene. The invention includes the attenuated viruses made by the method, antibodies generated using these viruses, and vaccines that can be used for immunizing cattle.
摘要翻译：本发明涉及通过突变Npro蛋白酶基因产生减毒形式的牛病毒性腹泻（BVD）病毒的方法。本发明包括通过该方法制备的减毒病毒，使用这些病毒产生的抗体，以及可用于免疫牛的疫苗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式